This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (Currently Amended): A compound of formula I

in which

is H, =O, COOR<sup>3</sup>, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, -OCOR<sup>3</sup>, NHCOA or NHSO<sub>2</sub>A,

 $R^2$  is H, =0, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

 $R^1$  and  $R^2$  together can also be a spirocyclically bonded 3- to 6-membered carbocyclic ring,

 $R^4$ ,  $R^2$  are each, independently of one another, H, =O, Hal, A, ethynyl,  $OR^3$ ,  $N(R^3)_{27}$ ,  $NO_2$ , CN,  $N_3$ ,  $COOR^3$ ,  $CON(R^3)_2$ ,  $-[C(R^4)_2]_n$ -Ar,  $-[C(R^4)_2]_n$ -Het,  $-[C(R^4)_2]_n$ 
cycloalkyl,  $-OCOR^3$ ,  $-OCON(R^3)_2$ ,  $NR^3COA$ , or  $NR^3SO_2A$ .

R<sup>1</sup> and R<sup>2</sup> together are alternatively a bicyclically or spirocyclically bonded 3- to 7-membered carbocyclic or heterocyclic ring having from 0 to 3 N, O and/or S atoms,

$$\begin{split} R^{3} & \quad \underline{\text{is H or A, is H, A, H-C}} \underline{\text{C-CH}}_{2}\underline{\text{-, CH}}_{3}\underline{\text{-C}}\underline{\text{-C-CH}}_{2}\underline{\text{-, -CH}}_{2}\underline{\text{-CH}}(OH)\underline{\text{-CH}}_{2}OH, \\ & \quad \underline{\text{-CH}}_{2}\underline{\text{-CH}}(OH)\underline{\text{-CH}}_{2}NH_{2}\underline{\text{-, -CH}}_{2}\underline{\text{-CH}}(OH)\underline{\text{-CH}}_{2}Het', -[C(R^{4})_{2}]_{\mathfrak{n}}\underline{\text{-Ar'}}, -[C(R^{4})_{2}]_{\mathfrak{n}}\underline{\text{-COOA or -[C(R^{4})_{2}]_{\mathfrak{n}}N(R^{4})}_{2}\underline{\text{-}}, \\ & \quad \underline{\text{Het'}}, -[C(R^{4})_{2}]_{\mathfrak{n}}\underline{\text{-cycloalkyl}}, -[C(R^{4})_{2}]_{\mathfrak{n}}\underline{\text{-COOA or -[C(R^{4})_{2}]_{\mathfrak{n}}N(R^{4})}_{2}\underline{\text{-}}, \end{split}$$

 $R^4$  is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or

- azetidine-1,2-diyl,
- W is N, CR<sup>3</sup> or an sp<sup>2</sup> hybridised carbon atom,
- E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atom which optionally contains a double bond,
- D is phenyl, pyridyl or thienyl, which in each case is monosubstituted or disubstituted by Hal, a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>3</sup> or CON(R<sup>3</sup>)<sub>2</sub>,
- G is  $(CH_2)_n$  or  $(CH_2)_nNH_{-}$ ,  $-[C(R^4)_2]_n$ ,  $-[C(R^4)_2]_nNR^3$ ,  $-[C(R^4)_2]_nO_{-}$ ,  $-[C(R^4)_2]_nS_{-}$ or  $-[C(R^4)_2]_n$ ,
- $\begin{array}{lll} X & \text{ is } \underline{CONH}, -[C(R^4)_2]_n \underline{CONR^3}[C(R^4)_2]_n [C(R^4)_2]_n NR^3 \underline{CO[C(R^4)_2]_n} \\ & -[C(R^4)_2]_n NR^3[C(R^4)_2]_n [C(R^4)_2]_n \underline{O[C(R^4)_2]_n} [C(R^4)_2]_n \underline{CO[C(R^4)_2]_n} \underline{OFC(R^4)_2}_n \underline$
- Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F, alkylene, eycloalkylene, Het diyl or Ar diyl,
- is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen, a monocyclic or bicyclic, saturated or unsaturated carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by =O, =S, =NR³, =N CN, =N NO₂, =NOR³, =NCOR³, =NCOOR³ or =NOCOR³ and which is optionally further monosubstituted, disubstituted or trisubstituted by R³, Hal, A, -[C(R⁴)₂]<sub>n</sub>-Ar, -[C(R⁴)₂]<sub>n</sub>-Het, -[C(R⁴)₂]<sub>n</sub> eycloalkyl, OR³, N(R³)₂, NO₂, CN, COOR³, CON(R³)₂, NR³COA, NR³CON(R³)₂, NR³SO₂A, COR³, SO₂NR³ and/or S(O)<sub>n</sub>A,
- A is <u>unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H</u>

  <u>atoms are each optionally replaced by F, unbranched or branched alkyl having 1-10 carbon atoms in which one or two CH<sub>2</sub> groups are each optionally replaced by O or S atoms and/or by -CH=CH- groups and/or in addition 1-7 H</u>

atoms are each optionally replaced by F,

- Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>3</sup>, CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>COA, NR<sup>3</sup>CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>SO<sub>2</sub>A, COR<sup>3</sup>, SO<sub>2</sub>N(R<sup>3</sup>)<sub>2</sub>, S(O)<sub>n</sub>A, [C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>3</sup> or O[C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>3</sup>,
- Ar' is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR<sup>4</sup>, N(R<sup>4</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>4</sup>, CON(R<sup>4</sup>)<sub>2</sub>, NR<sup>4</sup>COA, NR<sup>4</sup>CON(R<sup>4</sup>)<sub>2</sub>, NR<sup>4</sup>SO<sub>2</sub>A, COR<sup>4</sup>, SO<sub>2</sub>N(R<sup>4</sup>)<sub>2</sub>, S(O)<sub>n</sub>A, [C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>4</sup> or O[C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>4</sup>;
- Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, [C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub> Ar, [C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub> Het', [C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub> cycloalkyl, OR<sup>3</sup>, N(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>CON(R<sup>3</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, [C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub> COOR<sup>3</sup>, [C(R<sup>4</sup>)<sub>2</sub>]<sub>n</sub> CON(R<sup>3</sup>)<sub>2</sub>, NR<sup>3</sup>COA, NR<sup>3</sup>SO<sub>2</sub>A, COR<sup>3</sup>, SO<sub>2</sub>NR<sup>3</sup>, S(O)<sub>m</sub>A and/or carbonyl oxygen,
- Het' is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, =S, =N(R<sup>4</sup>)<sub>2</sub>, Hal, A, OR<sup>4</sup>, N(R<sup>4</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>4</sup>, CON(R<sup>4</sup>)<sub>2</sub>, NR<sup>4</sup>COA, NR<sup>4</sup>CON(R<sup>4</sup>)<sub>2</sub>, NR<sup>4</sup>SO<sub>2</sub>A, COR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup> and/or S(O)<sub>n</sub>A,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2, and

o is 1, 2 or 3:

or a and pharmaceutically usable <u>prodrug</u> derivative, solvate, salt, or stereoisomer thereof, including mixtures thereof in all ratios,

wherein said pharmaceutically usable prodrug derivative is a compound of formula I which has been modified with an alkyl group, acyl groups, sugar, oligopeptide, or biodegradable polymer and which is cleavable to form a compound of formula I.

## 2. (Cancelled):

3.	(Cancelled):	
4.	(Cancelled):	
5.	(Cancelled):	
6.	(Cancelled):	
7.	(Cancelled):	
8.	(Cancelled):	
9.	(Cancelled):	
10.	(Cancelled):	
11.	(Cancelled):	
12.	(Cancelled):	
13.	(Cancelled):	
14.	(Cancelled):	
15.	(Cancelled):	
16.	(Cancelled):	
17.	(Cancelled):	
18.	(Cancelled):	

- 19. (Cancelled):
- 20. (Cancelled):
- 21. (Cancelled):
- 22. (Cancelled):
- 23. (Currently Amended): A compound according to Claim 1, wherein said compound is selected from:
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-piperidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)] 2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]} (R) pyrrolidine-1,2-dicarboxamide,
- $\frac{1-N-[(4-chlorophenyl)]-2-N-\{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]\}-(R)-pyrrolidine}{1,2-dicarboxamide,}$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,$
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

- N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-oxazolidine-3, 4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)-4-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(2-oxo-2H-pyridin-1-yl)phenyl]\}-(R)-oxazolidine-3,4-dicarboxamide,$
- 3 N [(4 chlorophenyl)] 4 N {[4 (2 oxo 2H pyridin 1 yl)phenyl]} (4R,5S) 5 methyloxazolidine 3,4-dicarboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(4R,5S)-5-methyloxazolidine 3,4-dicarboxamide,
- 3 N [(4 chlorophenyl)] 4 N {[4 (2 oxo 2H pyrazin 1 yl)phenyl]} (R) oxazolidine 3,4-dicarboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-[[3-chloro-4-(2-oxo-2H-pyridin-1-yl)phenyl]]-(R)-oxazolidine-3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-thiazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-1,1-dioxo-1\lambda^6-thiazolidine-3,4-dicarboxamide,$

- $3-N-[(4-chlorophenyl)]-4-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-thiazolidine-3,4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo- $1\lambda^6$ -thiazolidine-3,4-dicarboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-thiazolidine-3,4-dicarboxamide,
- N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl) oxazolidine-5-carboxamide,
- N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,
- N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,
- 1 N [(5 chloropyridin 2 yl)] 2 N {[4 (2 oxo 2H pyridin 1 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide,
- $1-N-[(5-chloropyridin-2-yl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- 1 N [(5 chloropyridin 2 yl)] 2 N {[4 (2 oxo 2H pyrazin 1 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide.
- 1-N-[(5-chloropyridin-2-yl)]-2-N-[[3-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2 dicarboxamide,
- 1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

- 1 N [(4 chlorophenyl)] 2 N {[4 (2 oxo 2*H* pyridin 1 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-[[4-(2-oxopyrazin-1-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1 N [(4 chlorophenyl)] 2 N {[3 fluoro 4 (2 oxo 2*H* pyridin 1 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,$

- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,$
- (3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl isobutyrate,
- (3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl propionate,
- (3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl] pyrrolidin-3-yl acetate,
- $\label{lem:continuous} 4-N-[(4-chlorophenyl)]-5-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-4, 5-dicarboxamide,$
- $\label{lem:continuous} 4-N-[(4-chlorophenyl)]-5-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-1,3-dioxolane-4,5-dicarboxamide,$
- 4 N [(4 chlorophenyl)] 5 N {[4 (2 oxo 2*H* pyridin 1 yl)phenyl]} 1,3 dioxolane 4,5 dicarboxamide,
- $\label{lem:continuous} 4-N-[(4-chlorophenyl)]-5-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-2, 2-dimethyl-4, 5-dicarboxamide,$
- 4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,
- 4 N [(4 chlorophenyl)] 5 N {[4 (2 oxo 1*H* pyridin 1 yl)phenyl]} 1,3 dioxolane 2,2 dimethyl-4,5 dicarboxamide,

- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1-BOC-piperazine-1,2-dicarboxamide,$
- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\} piperazine-1, 2-dicarboxamide,$
- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-oxazinane-3, 4-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- 6-N-[(4-chlorophenyl)]-7-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,
- 1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1 N [(6 chloropyridin 3 yl)] 2 N {[4 (2 oxo 2H pyrazin 1 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-4-oxopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[2-(4-chlorophenyl)acetyl]-4-hydroxypyrrolidine-2-carboxamide,
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-4-hydroxypyrrolidine-2-carboxamide,

- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-[[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]]-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- 1 N [(4 chlorophenyl)] 2 N {[4 (2 oxo 2*H* pyrazin 1 yl)phenyl]} (2R,4R) 4 methoxypyrrolidine 1,2 dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,
- N-[4-(3-oxomorpholin-4-yl)phenyl] (2R,4R) 1-(1-1*H*-indol-3-ylmethanoyl) 4-hydroxypyrrolidine 2 carboxamide,
- N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 (1 1*H* indol 6 ylmethanoyl) 4 hydroxypyrrolidine 2-carboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- 1 N [(4 chlorophenyl)] 2 N {[4 (2 oxo 1*H* pyridin 1 yl)phenyl]} (2R,4R) 4 ethoxypyrrolidine 1,2 dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1 N [(4 chlorophenyl)] 2 N {[4 (2 oxo 2*H* pyrazin 1 yl)phenyl]} (2R,4S) 4 ethynyl 4 hydroxypyrrolidine 1,2 dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4,4-difluoro-(R)-pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- 1 N [(4 chlorophenyl)] 2 N {[2 fluoro 4 (2 oxo 2H pyridin 1 yl)phenyl]} (R) pyrrolidine-1,2-dicarboxamide,

1 N [(4 chlorophenyl)] 2 N {[2 fluoro 4 (2 oxo 2*H* pyridin 1 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide,

 $2-N-[(4-chlorophenyl)]-1-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide,$ 

 $2-N-[(4-chlorophenyl)]-1-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-pyrrolidine-1, 2-dicarboxamide,$ 

1 N [(4 chlorophenyl)] 2 N {[4 (2 oxo 3 methoxy 2H pyridin 1 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide,

1-N-[(4-chlorophenyl)] 2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

 $N-(4-chlorophenyl)-(R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl] acetyl\} pyrrolidine-2-carboxamide,$ 

 $N-(4-chlorophenyl)-(S)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl] acetyl\} pyrrolidine-2-carboxamide,$ 

 $N-(4-chlorophenyl)-(2R,4R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,$ 

 $N-(4-chlorophenyl)-(2R,4S)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,\\$ 

 $N-(4-chlorophenyl)-(2S,4R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,$ 

 $N-(4-chlorophenyl)-(S)-1-\{2-[4-(2-oxo-1H-pyridin-1-yl)phenyl]acetyl\} pyrrolidine-2-carboxamide,$ 

N (4 chlorophenyl) (S) 1 {2 [4 (2 oxopyrrolidin 1 yl)phenyl]acetyl}pyrrolidine 2 carboxamide,

N-(4-chlorophenyl) (R) 1-[2-[4-(2-oxopyrrolidin-1-yl)phenyl]acetyl]pyrrolidine 2-carboxamide,

N-(4-chlorophenyl) (R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-earboxamide,

N (4 chlorophenyl) (R) 1 [4 (2 oxopiperidin 1 yl)phenyloxycarbonyl]pyrrolidine 2 carboxamide,

1 N [(4 chlorophenyl)] 2 N {[4 (2 oxo 2H pyrazin 1 yl)phenyl]} (2R,4R) 4 ethoxypyrrolidine 1,2 dicarboxamide,

 $1-N-[(4-chlorophenyl)]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,\\$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2-oxooxazolidin-5-ylmethoxy)pyrrolidine-1,2-dicarboxamide,$ 

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1 N [(4 chlorophenyl)] 2 N {[4 (2 oxo 1*H* pyrazin 1 yl)phenyl]} (R) 2,5 dihydropyrrole 1,2 dicarboxamide.

1-N-[(4-chlorophenyl)]-2-N-[[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]]-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

 $1-N-[(4-chlorophenyl)]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2S,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,$ 

1 N [(4 chlorophenyl)] 2 N {[2 methoxycarbonyl 4 (3 oxomorpholin 4 yl)phenyl]}-(2R,4R) 3 hydroxypyrrolidine 1,2 dicarboxamide,

- $1-N-[(4-chlorophenyl)]-2-N-\{[2-carboxy-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-bromophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,
- $\frac{1-N-[(4-chlorophenyl)]-2-N-[N-methoxycarbonylmethyl-N'-[4-(3-oxomorpholin-4-yl)phenyl]]-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,}{}$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)cyclohexan-1-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1 N [(4 chlorophenyl)] 2 N {[4 (2 iminopyrrolidin 1 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine-1,2-dicarboxamide;
- 1-N-[(4-chlorophenyl)] 2-N-{[3-methyl-4-(2-iminopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide;
- 1-N-[(4-chlorophenyl)]-2-N-[4-{2-[(E)-cyanimino]imidazolidin-1-yl)phenyl]}-(2R,4R) 4 hydroxypyrrolidine 1,2 dicarboxamide;
- 1 N [(4 chlorophenyl)] 2 N {[4 (2 imino 5 methylthiazol 3 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine-1,2-dicarboxamide;

1-N-[(4-chlorophenyl)]-2-N-{[2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide;

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxy-2-methylpyrrolidine-1,2-dicarboxamide,$ 

N [4 (3-oxomorpholin 4-yl)phenyl] (2R,4R) 1 [(E) 3 (5-chlorothiophen 2-yl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 thiophen 3 ylacryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(2E,4E) 5 phenylpenta 2,4-dienyloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-methylfuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 thiophen 2 ylacryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorothiophen 2 yl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4 hydroxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (4 chlorophenyl)acryloyl] 4 methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorothiophen 2 yl)acryloyl] 4 methoxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorofuran 2 yl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorofuran 2 yl)acryloyl] 4 methoxypyrrolidine 2 carboxamide.

N-[4-(3-oxomorpholin-4-yl)phenyl] (2R,4R) 1-[(E) 3-(4-chlorophenyl)acryloyl] 4-ethoxypyrrolidine 2-carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (3,4 dichlorophenyl)acryloyl] 4 ethoxypyrrolidine 2 carboxamide,

N [4-(3-oxomorpholin-4-yl)phenyl] (2R,4R) 1 [(E) 3 (5-chlorofuran-2-yl)acryloyl] 4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (4 chlorophenyl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorofuran 2 yl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl] 4 methoxypyrrolidine 2 carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (3,4-dichlorophenyl)acryloyl] 4 methoxypyrrolidine 2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorofuran 2 yl)acryloyl] 4 ethoxypyrrolidine 2 carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 chlorothiophen 2 yl)acryloyl] 4 ethoxypyrrolidine 2 carboxamide,

N-[4 (3-oxomorpholin-4-yl)phenyl] (2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl] (2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl] 4-hydroxypyrrolidine 2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 1H imidazol 4 ylacryloyl] 4 methoxypyrrolidine 2 carboxamide,

N-[2-fluoro-4 (3-oxomorpholin 4-yl)phenyl] (2R,4R) 1-[(E)-3-1*H*-imidazol-4-ylacryloyl] 4-ethoxypyrrolidine 2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine 2-carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 pyridin 3 ylacryloyl] 4 ethoxypyrrolidine 2 carboxamide,

N-[2-fluoro-4 (3-oxomorpholin-4-yl)phenyl] (2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N [2 fluoro 4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 pyridin 3 ylacryloyl] 4 ethoxypyrrolidine 2 carboxamide,

 $\frac{N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,}{}$ 

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine 2-carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 pyridin 4 ylacryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine 2-carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (4 bromothiophen 2 yl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (4 bromothiophen 2 yl)acryloyl] 4 ethoxypyrrolidine 2 carboxamide,

N [4 (3 oxomorpholin 4 yl)phenyl] (2R,4R) 1 [(E) 3 (5 bromothiophen 2 yl)acryloyl] 4 hydroxypyrrolidine 2 carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N (4 chlorophenyl) (R) 1 [4 (2 oxopiperidin 1 yl)benzoyl]pyrrolidine 2 carboxamide,

N-(4-chlorophenyl)-(S)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide.

1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1 N [(4 chlorophenyl)] 2 N {[4 (5 oxo 1,4 oxazepan 4 yl)phenyl]} (2R,4R) 4 hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)] 2-N-[[4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl]]-(2R,4R) 4-hydroxypyrrolidine-1,2-dicarboxamide,

1 N [(4 chlorophenyl)] 2 N {[4 ((S) 2 methyl 3 oxomorpholin 4 yl)phenyl]} (2R) pyrrolidine 1,2 dicarboxamide,

 $\frac{1-N-[(4-chlorophenyl)]-2-N-\{[4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,}{}$ 

1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2 dicarboxamide,

1 N [(4 chlorophenyl)] 2 N {[4 (3 oxomorpholin 4 yl) 2 phenoxyphenyl]} (2R) pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[2-fluoro-4-((R)-2-methyl-3-oxomorpholin-4-yl)-phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

 $1-N-[(4-chlorophenyl)]-3-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\} piperidine-1, 3-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-3-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\} piperidine-1,3-dicarboxamide,$ 

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[[4-(3-oxo-1,4-oxazepan-4-yl)phenyl]]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

 $1-N-[(4-chlorophenyl)]-2-N-\{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$ 


 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$ 

 $1-N-[(4-chlorophenyl)]-2-N-\{[2-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$ 

and pharmaceutically usable <u>prodrug</u> derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 24. (Cancelled):
- 25. (Cancelled):
- 26. (Withdrawn; Currently Amended): A process for the preparation of compounds of the formula I according to claim 1 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, said process comprising
- a) for the preparation of compounds of the formula I in which  $\,W$  is  $\,N$  and  $\,G$  is  $\,NH,\,$

a compound of formula II



in which

R<sup>1</sup>, R<sup>2</sup>, E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of formula III

in which

D is as defined in Claim 1,

<del>or</del>

b) for the preparation of compounds of formula I in which X is  $[C(R^4)_2]_nCONR^3[C(R^4)_2]_n$ -,

a compound of formula IV

in which R<sup>3</sup>, n, Y and T are as defined in Claim 1,

is reacted with a compound of formula V

in which

L is Cl, Br, I or a free or reactively functionally modified OH group, and R<sup>4</sup>, R<sup>2</sup>, R<sup>4</sup>, D, E, G, W and n are as defined in Claim 1,

or

c) for the preparation of compounds of formula I in which W is N,

a compound of formula II

$$R^{1} \xrightarrow{E} X^{R^{2}} X - Y - T$$

$$\downarrow \qquad \qquad \qquad \parallel$$

$$\downarrow \qquad \qquad \parallel$$

$$\downarrow \qquad \qquad \parallel$$

$$\downarrow \qquad \qquad \parallel$$

$$\downarrow \qquad \qquad \parallel$$

in which

R<sup>1</sup>, R<sup>2</sup>, E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of formula VI

in which

D and G are as defined in Claim 1, and L is Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

- 27. (Cancelled):
- 28. (Cancelled):
- 29. (Currently Amended): A medicament composition comprising at least one compound according to claim 1 and one <u>or ore</u> more excipients and/or adjuvants.
- 30. (Previously Presented): A medicament composition comprising at least one compound according to claim 1 and at least one further medicament active ingredient.


- 31. (Withdrawn): A method for the treatment of a patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to said patient an effective amount of a compound according to claim1.
  - 32. (Previously Presented): A kit comprising separate packs of:
  - (a) an effective amount of a compound according to claim 1,

and

- (b) an effective amount of a further medicament active ingredient.
- 33. (Withdrawn): A method according to claim 31, further comprising administering to said patient at least one further medicament active ingredient.
  - 34. (Cancelled):
  - 35. (Cancelled):
  - 36. (Cancelled):
  - 37. (Cancelled):
  - 38. (Cancelled):
  - 39. (Cancelled):
- 40. (Withdrawn; Currently Amended): A medicament composition according to Claim 30, wherein said at least one compound is 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or a pharmaceutically usable derivative, solvate, salt or <u>stereoisomer</u> stereoisomers thereof,


including mixtures thereof in all ratios, and <u>said</u> at least one further medicament active ingredient is aspirin.

- 41. (Withdrawn; Currently Amended): A method according to Claim 33, wherein 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxy-pyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivative, solvate, salt or stereoisomer stereoisomers thereof, including mixtures thereof in all ratios, and aspirin are administered to said patient.
  - 42. (Withdrawn; Currently Amended): A compound according to claim 1, wherein




is pyrrolidine-1,2-diyl,


- G is -NH-, and
- X is CONH<sub>7</sub>
- Y is Ar-diyl,
- Ar is phenyl which is substituted or unsubstituted; and
- T is pyrrolidin 1 yl, is monosubstituted or disubstituted by carbonyl oxygen.
- 43. (New): A compound according to claim 1, wherein R<sup>1</sup> is H, =O, COOA, OH, OA, NH<sub>2</sub>, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N<sub>3</sub>, ethynyl, vinyl, allyloxy, methylcarbonyloxy, acetamino, or methylsulfonylamino.
- 44. (New): A compound according to claim 1, wherein  $R^2$  is H, =O, OH, methoxy, or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.
  - 45. (New): A compound according to claim 1, wherein R<sup>4</sup> is H.
  - 46. (New): A compound according to claim 1, wherein




- 47. (New): A compound according to claim 1, wherein E is piperidine-1,2-diyl.
- 48. (New): A compound according to claim 1, wherein E is oxazolidine-3,4- or 3,5-diyl.
- 49. (New): A compound according to claim 1, wherein E is thiazolidine-3,4-diyl.
- 50. (New): A compound according to claim 1, wherein E is 2,5-dihydro-1H-pyrrole-1,5-diyl.
- 51. (New): A compound according to claim 1, wherein E is 1,3-dioxolane-4,5-diyl.
- 52. (New): A compound according to claim 1, wherein E is 1,3-oxazinane-3,4-diyl.
  - 53. (New): A compound according to claim 1, wherein



54. (New): A compound according to claim 1, wherein



55. (New): A compound according to claim 1, wherein



- 56. (New): A compound according to claim 1, wherein D is phenyl which is monosubstituted or disubstituted by Hal.
- 57. (New): A compound according to claim 1, wherein D is pyridyl which is monosubstituted or disubstituted by Hal.
- 58. (New): A compound according to claim 1, wherein D is thienyl which is monosubstituted or disubstituted by Hal.
  - 59. (New): A compound according to claim 1, wherein G is  $(CH_2)_n$ .
  - 60. (New): A compound according to claim 1, wherein G is  $(CH_2)_nNH$ -.